Manufacturer record
Malik Lifesciences Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
8 batches manufactured by Malik Lifesciences Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between August 2024 and September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: BLM03ACA, Methylprednisolone Tablets IP 16 mg (exp Oct 2027). RDTL, Ernakulam (state lab) found it not of standard quality: Sample does not conforms to Indian Pharmacopiea 2026 standards. This particular batch of sample fails in the test " Dissolution". Listed in the September 2026 alert.
Records by type
8 records linked to Malik Lifesciences Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Methylprednisolone Tablets IP 16 mg | Batch BLM03ACAMfg Nov 2025 · Exp Oct 2027 | Sample does not conforms to Indian Pharmacopiea 2026 standards. This particular batch of sample fails in the test " Dissolution".Dissolution | RDTL , ErnakulamState lab | Sep 2026 |
| Cofixime, Cloxacillin & Lactic Acid Bacillus Tablets | Batch 6926C002Mfg Mar 2026 · Exp Feb 2028 | The sample does not conform to declared formula in respect of Disintegration Test.Disintegration | LUCKNOW, Uttar PradeshState lab | Sep 2026 |
| Amoxycillin and Potassium Clavulanate Oral Suspension IP 228.5 mg | Batch GPF01ABBMfg Feb 2026 · Exp Jul 2027 | The sample for the reasons given be.ow:- does not conforms to I.P. in respect of content of Amoxycillin and Clavulanic Acid.Other | Meerut, Uttar PradeshState lab | Sep 2026 |
| Amoxycillin and Potassium Clavulanate Tablets IP | Batch CBZ19ADAMfg Dec 2025 · Exp Nov 2027 | Dissolution of AmoxycillinDissolution | Lucknow LabState lab | Jul 2026 |
| Amoxycillin & Cloxacillin Capsules | Batch ZABG2611Mfg May 2026 · Exp Oct 2027 | The sample does not conform to Manufacture's Specification with respect to the test for Assay of Amoxycillin Trihydrate eq. to Amoxycillin and Cloxacillin Sodium equivalent to Cloxacillin and Dissolution Cloxacillin Sodium equivalent to CloxacillinAssay | CDTL, IndoreCDSCO lab | Jul 2026 |
| Thyroxine Sodium Tablets IP 25 mcg | Batch BGL06AABMfg Jan 2026 · Exp Dec 2027 | Dissolution.Dissolution | DTL ThrissurState lab | May 2026 |
| Amoxycillin Capsules IP 250mg (Amoxi 250) | Batch MT14AC08Mfg Aug 2023 · Exp Jul 2025 | Does not comply with respect to test for AssayAssay | State lab , PuducherryState lab | May 2025 |
| Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) | Batch MD19AA08Mfg Oct 2023 · Exp Sep 2025 | Assay and Uniformity of content of Clavulanic Acid and Dissolution of Amoxycillin and Clavulanic AcidAssay | RDTL GuwahatiCDSCO lab | Aug 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.